Quick Answer
RELMADA THERAPEUTICS, INC. reported Diluted EPS of $1.45 per share (loss) for fiscal year 2025.
RELMADA THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.45 | +45.3% |
| 2024 | -$2.65 | +19.2% |
| 2023 | -$3.28 | +38.1% |
| 2022 | -$5.30 | +26.0% |
| 2021 | -$7.16 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.30 | +58.3% | +0.0% |
| June 30, 2025 | -$0.30 | +49.2% | +48.3% |
| March 31, 2025 | -$0.58 | +19.4% | +19.4% |
| September 30, 2024 | -$0.72 | +1.4% | -22.0% |
| June 30, 2024 | -$0.59 | +29.8% | +18.1% |
| March 31, 2024 | -$0.72 | +17.2% | +1.4% |
| September 30, 2023 | -$0.73 | +44.3% | +13.1% |
| June 30, 2023 | -$0.84 | +36.8% | +3.4% |
- RELMADA THERAPEUTICS, INC. showed an increase of +45.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, RELMADA THERAPEUTICS, INC.’s diluted eps has grown by 79.7% (from $7.16 per share (loss) to $1.45 per share (loss)).
- The most recent figure is from RELMADA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: